-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

125 Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Program: Oral and Poster Abstracts
Type: Oral
Session: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Viral, Genetic Disorders, Diseases, Infectious Diseases
Saturday, December 7, 2024: 1:00 PM

Xinyue Deng1,2*, Qiang Gao1,2*, Kefeng Shen1,2*, Wei Mu1,2*, Tong Ge, MD, PhD1,2*, Jiachen Wang, MD, PhD1,2*, Jianfeng Zhou, MD, PhD1,2*, Yicheng Zhang1,2*, Dengju Li, PhD1,2 and Min Xiao, MD, PhD1,2*

1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Department of Scientific Research Management, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

INTRODUCTION: Epstein-Barr virus (EBV) is a commonly distributed herpes virus. EBV usually infects B and epithelial cells, but it is also able to infect T and natural killer (NK) cells and trigger the intractable EBV-associated T/NK lymphoproliferative diseases (EBV-T/NK-LPDs) in rare cases. There exists a large number of patients without any pathogenic gene variants despite several genetic defects such as those in UNC13D and LYST being identified in primary EBV-T/NK-LPDs. In the authors’ previous retrospective study, the germline tumor necrosis factor (TNF)-TNF receptor (TNFR) superfamily members variants were recurrently found in non-primary EBV-T/NK-LPDs patients, with the TNFRSF13B exon 2 variants being the most frequent. The signaling interactions between TACI (encoded by TNFRSF13B) and EBV-encoded proteins, and the physiological process shared by EBV lytic reactivation and plasma cell differentiation, strongly indicate that TACI variants alter the anti-EBV responses in multiple aspects. In this study, we revealed the imbalanced expression of TACI isoforms caused by distinct TACI variants, investigated the possible mechanisms of TACI variants-mediated alterations of EBV activity, and discussed the possible TACI-targeted therapies for EBV-T/NK-LPDs. This preliminary research provided a novel future direction for decoding EBV infection and anti-EBV immunity.

METHODS: To investigate the role of recurrent TNFRSF13B variants in the process of EBV infection and immortalization, B lymphoblastoid cell lines (B-LCL) models carrying homozygous TNFRSF13B exon 2 frameshift deletions/insertions was successfully constructed using the CRISPR/Cas9 technique. Several examinations are performed to clarify the influences of TACI variants in EBV-infected B cells, including the TACI expression, cell viability, B-lineage immunophenotype, the activation of downstream signaling pathways, the EBV lytic replication/latency program, and the secretion of cytokines. To verify the potentials of TNFRSF13B-targeting therapy in EBV-LPDs, drugs that regulate TACI expression or the TACI-mediated signaling were applied in B-LCL models. Finally, the possible mechanisms of TACI-mediated EBV reactivation in the immortalized B cells were investigated primarily through transcriptomic analysis and subsequent validation experiments.

RESULTS: In the cohort of previous research, six non-primary EBV-T/NK-LPD patients carry rare heterozygous pathogenic germline TNFRSF13B variants, of which 5 mutations were located at the exon 2 of this gene. Introducing frameshift deletions/insertions at the exon 2 of TNFRSF13B in healthy donor-derived B-LCLs diminished the expression of long isoforms of TACI (TACI-L) but significantly upregulated the short isoforms of TACI (TACI-S). The enhanced expression of TACI-S delivered more intense activation of NF-κB, MAPK, Rho, and PI3K/AKT pathways, induced the reactivation of EBV lytic replication in LCLs, promoted the secretion of viral interleukin (IL)-10 and pro-inflammatory cytokines, ultimately led to the significantly increased EBV loads, rendering the carriers susceptible to EBV-LPDs. Furthermore, the low-affinity 3-mer forms of TACI ligand, B cell-activating factor (BAFF), and a proliferation-inducing ligand (APRIL) significantly reduced TACI signaling, suppressing the EBV lytic program, and thus alleviating the EBV infection in B-LCLs. The AKT signaling suppressor TUSC3 differently expressed in TACI exon 2 variant-expressing and wild-type B-LCLs, might mediate the TACI-associated EBV lytic reactivation.

CONCLUSIONS: This research proposes that the TNFRSF13B variants play important roles during the process of EBV-LPD development by regulating the expression of TACI isoforms. For patients who carry the gain-of-function germline mutations of TNFRSF13B, the inhibitory TACI-Ig or the TACI ligands BAFF and APRIL may efficiently prevent the serious progression of their EBV infection. Screening for possibly pathogenic variants, especially in the TNF-TNFR superfamily genes in EBV-LPD patients is necessary and valuable for understanding the pathogenesis of EBV-LPDs and optimizing the therapeutic regimen.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH